BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Dimitrios A. Koutoukidis, Nerys M. Astbury, Kate E. Tudor, Elizabeth Morris, John A. Henry, Michaela Noreik, Susan A. Jebb, Paul Aveyard. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver DiseaseJAMA Internal Medicine 2019; 179(9): 1262 doi: 10.1001/jamainternmed.2019.2248
2
Mika Aizawa, Seiichi Inagaki, Michiko Moriyama, Kenichiro Asano, Masayuki Kakehashi, Ying-Mei Feng. Modeling the natural history of fatty liver using lifestyle–related risk factors: Effects of body mass index (BMI) on the life–course of fatty liverPLOS ONE 2019; 14(10): e0223683 doi: 10.1371/journal.pone.0223683
3
Tonya Paris, Elena S. George, Stuart K. Roberts, Audrey C. Tierney. The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver diseaseEuropean Journal of Gastroenterology & Hepatology 2017; 29(8): 867 doi: 10.1097/MEG.0000000000000890
4
Kate Hallsworth, Leon A. Adams. Lifestyle modification in NAFLD/NASH: Facts and figuresJHEP Reports 2019; 1(6): 468 doi: 10.1016/j.jhepr.2019.10.008
5
Newaz Hossain, Pushpjeet Kanwar, Smruti R. Mohanty. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLDGastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/7109270
6
Manuel Romero-Gómez, Shira Zelber-Sagi, Michael Trenell. Treatment of NAFLD with diet, physical activity and exerciseJournal of Hepatology 2017; 67(4): 829 doi: 10.1016/j.jhep.2017.05.016
7
Yukihiro Bando, Ayumi Ogawa, Kazuhide Ishikura, Hideo Kanehara, Azusa Hisada, Kazuo Notumata, Kazuhiro Okafuji, Daisyu Toya. The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitusDiabetology International 2017; 8(2): 218 doi: 10.1007/s13340-016-0302-y
8
Giulio Marchesini, Salvatore Petta, Riccardo Dalle Grave. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practiceHepatology 2016; 63(6): 2032 doi: 10.1002/hep.28392
9
Pushpjeet Kanwar, Kris V. Kowdley. The Metabolic Syndrome and Its Influence on Nonalcoholic SteatohepatitisClinics in Liver Disease 2016; 20(2): 225 doi: 10.1016/j.cld.2015.10.002
10
Maureen Whitsett, Lisa B VanWagner. Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic reviewWorld Journal of Hepatology 2015; 7(16): 2041-2052 doi: 10.4254/wjh.v7.i16.2041
11
Siôn A. Parry, Leanne Hodson. Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative ReviewAdvances in Therapy 2020; 37(4): 1381 doi: 10.1007/s12325-020-01281-6
12
G. Targher, G. Marchesini, C.D. Byrne. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?Diabetes & Metabolism 2016; 42(3): 142 doi: 10.1016/j.diabet.2016.04.002
13
Christina N Katsagoni, Michael Georgoulis, George V Papatheodoridis, Demosthenes B Panagiotakos, Meropi D Kontogianni. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysisMetabolism 2017; 68: 119 doi: 10.1016/j.metabol.2016.12.006